Clinical Trials · NCT07284979
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
- Phase
- Phase 3
- Recruitment status
- Recruiting
- Sponsor
- Kailera
- Enrollment
- 1,200
- Start date
- Dec 2025
- Locations
- 34 sites, United States, Australia
- Primary endpoint
- Percent Change From Baseline in Body Weight at Week 76